DarioHealth Corp.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US23725P2092
USD
12.05
0.16 (1.35%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About DarioHealth Corp. stock-summary
stock-summary
DarioHealth Corp.
Pharmaceuticals & Biotechnology
DarioHealth Corp. (DarioHealth) is a Digital Therapeutics (DTx) company. DarioHealth operates at the intersection of life sciences, behavioral science, and software technology to deliver integrated and engaging digital therapeutics interventions. The DTx products are centered around its users and include the Dario Blood Glucose Monitoring System and the Dario Smart Diabetes Management Solution, which are provided to its users in the form of a smartphone application that enables the delivery of content and periodical evidence-based reports; the DarioEngage platform, which provides support and two-way real-time connectivity between its users and their caregivers, and Dario Intelligence, which utilizes user data and is an analytics tool that can assist healthcare providers in the treatments and predictability of diseases. The Company’s services are available direct to consumers via online marketplaces including Amazon, Walmart, Best Buy and the Google and Apple app stores.
Company Coordinates stock-summary
Company Details
8 Hatokhen St. , CAESAREA None : 38900
stock-summary
Tel: 972 3 6222929
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Foreign Institutions

Domestic Funds

Held in 5 Schemes (2.13%)

Foreign Institutions

Held by 13 Foreign Institutions (8.01%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Yoav Shaked
Independent Chairman of the Board
Mr. Erez Raphael
Chief Executive Officer, Director
Dennis Matheis
Director
Mr. Adam Stern
Director
Mr. Allen Kamer
Independent Director
Ms. Hila Karah
Independent Director
Mr. Dennis McGrath
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
5 Million
(Quarterly Results - Jun 2025)
Net Profit:
-7 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 22 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

-53.24%

stock-summary
Price to Book

0.35